Shane Olwill - 01 Aug 2021 Form 3 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Role
Chief Development Officer
Signature
/s/ Megan Gates, Attorney-in-Fact
Issuer symbol
PVLA
Transactions as of
01 Aug 2021
Net transactions value
$0
Form type
3
Filing time
03 Aug 2021, 16:09:46 UTC
Next filing
01 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PIRS Common Stock 4,638 01 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 145,000 $2.00 Direct F1
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 100,000 $1.52 Direct F1
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 56,250 $1.99 Direct F1
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 90,000 $0.000000 Direct F2
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 82,000 $3.09 Direct F3
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 90,000 $3.15 Direct F4
holding PIRS Stock Option (right to buy) 01 Aug 2021 Common Stock 150,000 $2.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option has fully vested.
F2 The option vested as to 25% of the option shares on February 20, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
F3 The option vested as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
F4 The option vested as to 25% of the option shares on February 27, 2021 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
F5 The option vested as to 25% of the option shares on March 4, 2022 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.